This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Wall Street Analysts Think Surgery Partners (SGRY) Could Surge 57.53%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Surgery Partners (SGRY) points to a 57.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Teladoc (TDOC) Soars 6.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Teladoc (TDOC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Surgery Partners (SGRY) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Surgery Partners (SGRY) delivered earnings and revenue surprises of 42.86% and 1.38%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
DocGo Inc. (DCGO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Motion Acquisition (DCGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Surgery Partners (SGRY) Q1 Earnings Expected to Decline
by Zacks Equity Research
Surgery Partners (SGRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SGRY vs. DOCS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
SGRY vs. DOCS: Which Stock Is the Better Value Option?
Surgery Partners (SGRY) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Surgery Partners (SGRY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Believe Surgery Partners (SGRY) Could Rally 39.04%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Surgery Partners (SGRY) points to a 39% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Company News for Feb 27, 2024
by Zacks Equity Research
Companies in The News Are: DPZ,FRPT,SGRY,ITRI
The Zacks Analyst Blog Highlights Microsoft, Amazon.com, Surgery Partners, Nvidia and Occidental Petroleum
by Zacks Equity Research
Microsoft, Amazon.com, Surgery Partners, Nvidia and Occidental Petroleum are part of the Zacks top Analyst Blog.h